Small molecule · Inhibitor of Dopamine transporter (SLC6A3) and Norepinephrine transporter (SLC6A2) · developed by Axsome Malta
Solriamfetol is an oral small molecule that inhibits reuptake of dopamine and norepinephrine by binding their transporters. It is studied in excessive daytime sleepiness, including in narcolepsy, obstructive sleep apnea, shift-work disorder, and major depressive disorder with sleepiness symptoms, as well as in ADHD, insomnia, and pregnancy and postpartum settings.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 5, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05838430 | Phase 4 | Insomnia | Completed | AXSM |
| NCT04788953 | Phase 4 | Excessive Sleepiness | Terminated | AXSM |
| NCT04789174 | Phase 4 | Excessive Daytime Sleepiness | Completed | AXSM |
| NCT07717879 | Phase 3 | ADHD | Recruiting | AXSM |
| NCT07484217 | Phase 3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Recruiting | AXSM |
| NCT06568367 | Phase 3 | Excessive Sleepiness | Recruiting | AXSM |
| NCT05008341 | Phase 1 | Narcolepsy | Completed | AXSM |
| NCT06413420 | N/A | Narcolepsy | Recruiting | AXSM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ADHDPregnant Women and Their OffspringExcessive Daytime SleepinessExcessive Daytime SomnolenceExcessive SleepinessImpaired Cognitive FunctionInsomniaNarcolepsyObstructive Sleep ApneaPostpartumShift-work Disorder
Updated Oct 11, 2026. Something wrong or missing? Report it on the AXSM page.
See AXSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AXSM catalysts and pipeline →